DK3294283T3 - Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens - Google Patents

Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens Download PDF

Info

Publication number
DK3294283T3
DK3294283T3 DK16722388.2T DK16722388T DK3294283T3 DK 3294283 T3 DK3294283 T3 DK 3294283T3 DK 16722388 T DK16722388 T DK 16722388T DK 3294283 T3 DK3294283 T3 DK 3294283T3
Authority
DK
Denmark
Prior art keywords
sacubitril
treatment
heart failure
dosage regime
valsartan
Prior art date
Application number
DK16722388.2T
Other languages
English (en)
Inventor
Adel Redmond Rizkala
Victor Chengwei Shi
Fabian Chen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55967342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3294283(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3294283T3 publication Critical patent/DK3294283T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK16722388.2T 2015-05-11 2016-05-09 Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens DK3294283T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562159703P 2015-05-11 2015-05-11
PCT/IB2016/052633 WO2016181284A1 (en) 2015-05-11 2016-05-09 Sacubitril-valsartan dosage regimen for treating heart failure

Publications (1)

Publication Number Publication Date
DK3294283T3 true DK3294283T3 (da) 2023-05-30

Family

ID=55967342

Family Applications (2)

Application Number Title Priority Date Filing Date
DK23154757.1T DK4212152T3 (da) 2015-05-11 2016-05-09 Sacubitril-valsartan-doseringsregime til behandling af kronisk systolisk hjertesvigt
DK16722388.2T DK3294283T3 (da) 2015-05-11 2016-05-09 Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK23154757.1T DK4212152T3 (da) 2015-05-11 2016-05-09 Sacubitril-valsartan-doseringsregime til behandling af kronisk systolisk hjertesvigt

Country Status (15)

Country Link
US (2) US11058667B2 (da)
EP (3) EP4212152B1 (da)
JP (1) JP6576469B2 (da)
CY (1) CY1126036T1 (da)
DK (2) DK4212152T3 (da)
ES (2) ES3034658T3 (da)
FI (2) FI4212152T3 (da)
HR (2) HRP20230480T1 (da)
HU (2) HUE062195T2 (da)
LT (2) LT3294283T (da)
PL (2) PL3294283T3 (da)
PT (2) PT3294283T (da)
RS (2) RS64242B1 (da)
SI (2) SI3294283T1 (da)
WO (1) WO2016181284A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4212152B1 (en) 2015-05-11 2025-04-30 Novartis AG Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure
EP3117823A1 (en) * 2015-07-17 2017-01-18 Quimica Sintetica, S.A. Amorphous solid dispersion comprising an angiotensin receptor blocker and a neutral endopeptidase inhibitor
WO2019008485A1 (en) 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
WO2020106330A1 (en) * 2018-07-18 2020-05-28 Pillsy, Inc. Smart drug delivery and monitoring device, kit, and method of use for pill compounds
EP3840746A1 (en) * 2018-08-23 2021-06-30 Novartis AG New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
KR102752382B1 (ko) * 2019-09-20 2025-01-09 심천 사루브리스 퍼머수티칼스 컴퍼니 리미티드 안지오텐신 ii 수용체 길항제 대사물질 및 nep 억제제의 복합체의 심부전 치료에서의 용도
WO2021230664A1 (ko) * 2020-05-12 2021-11-18 에리슨제약(주) 사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97219A (en) 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
DK1467728T3 (da) 2002-01-17 2007-12-27 Novartis Ag Farmaceutiske sammensætninger indeholdende valsartan og NEP-inhibitorer
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP3067043B1 (en) 2007-11-06 2022-11-30 Novartis AG Pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
ES2879550T3 (es) 2012-08-24 2021-11-22 Novartis Ag Inhibidores de epn para tratar enfermedades caracterizadas por la dilatación o remodelación auriculares.
DK3038654T3 (da) 2013-08-26 2020-02-03 Novartis Ag Ny anvendelse
WO2015030711A1 (en) 2013-08-26 2015-03-05 Novartis Ag New use
EP4212152B1 (en) 2015-05-11 2025-04-30 Novartis AG Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure

Also Published As

Publication number Publication date
US11058667B2 (en) 2021-07-13
HUE062195T2 (hu) 2023-10-28
HUE071910T2 (hu) 2025-10-28
WO2016181284A1 (en) 2016-11-17
ES3034658T3 (en) 2025-08-21
US20180125820A1 (en) 2018-05-10
EP3294283B1 (en) 2023-03-08
US20220133694A1 (en) 2022-05-05
FI3294283T3 (fi) 2023-05-24
FI4212152T3 (fi) 2025-07-11
EP3294283A1 (en) 2018-03-21
PL4212152T3 (pl) 2025-08-11
EP4212152B1 (en) 2025-04-30
HRP20230480T1 (hr) 2023-07-21
SI3294283T1 (sl) 2023-07-31
EP4570314A3 (en) 2025-09-10
RS66936B1 (sr) 2025-07-31
PL3294283T3 (pl) 2023-07-24
EP4570314A2 (en) 2025-06-18
SI4212152T1 (sl) 2025-08-29
CY1126036T1 (el) 2023-11-15
PT3294283T (pt) 2023-06-07
DK4212152T3 (da) 2025-06-23
JP6576469B2 (ja) 2019-09-18
HRP20250779T1 (hr) 2025-08-29
RS64242B1 (sr) 2023-06-30
EP4212152A1 (en) 2023-07-19
LT3294283T (lt) 2023-06-12
LT4212152T (lt) 2025-07-10
PT4212152T (pt) 2025-07-08
ES2945866T3 (es) 2023-07-10
JP2018519266A (ja) 2018-07-19

Similar Documents

Publication Publication Date Title
DK3294283T3 (da) Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
IL258402A (en) Electroporation for obesity or diabetes treatment
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
HUE047477T2 (hu) Palbociclib szilárd dózisformái
DK3936130T3 (da) Doseringsskema for Valbenazin til behandling af hyperkinetiske bevægelsesforstyrrelser
DK3521282T3 (da) Quinazolinderivater anvendt til behandling af hiv
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3099333T3 (da) Bag3 som mål for behandling af hjertesvigt
DK3244948T3 (da) Bestemmelse af medikamentdosis
DK3253382T3 (da) Farmaceutiske sammensætninger til kombinationsterapi
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3102213T3 (da) Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser
DK3237045T3 (da) Indretning til indgivelse af lægemidler
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
DK3524255T3 (da) Sammensætning til behandling af acne
DK3324867T3 (da) Indretning til akut behandling af hjertestop
IL257355B (en) Selection of patients for combination therapy
HUE060517T2 (hu) Immunhiányos betegség kezelésére szolgáló eljárások
HRP20181572T1 (hr) Režim doziranja spoja fgf-18
DK3307267T3 (da) Behandling af multipel sklerose
DK3331610T3 (da) Midler til anvendelse til behandling af gliom
DK3468604T3 (da) Farmaceutiske kombinationer til behandling af cancer